If you have Empire Blue Cross Blue Shield health insurance, visit StayWithNYP.com to learn about how your in-network access to Weill Cornell Medicine physicians may be impacted.
Surgery

You are here

Clinical Trials

The Department of Surgery doesn’t just excel in the operating room. Through our extensive and innovative research programs, we are also focused on the development of new techniques and therapies that promote better outcomes and improve the quality of life for patients following surgery. 

As part of that goal, the department’s surgeons are involved in groundbreaking clinical trials. In addition to their research value, clinical trials may also give patients access to new treatments that are not available anywhere else.

Learn more about our current clinical trials below or visit the Joint Clinical Trials Office at Weill Cornell Medicine and NewYork-Presbyterian.

This clinical trial is for men and women diagnosed with ischemic heart disease (myocardial ischemia) who are eligible to be treated with coronary angioplasty (PCI).

This is a phase II, multi-center study to determine the efficacy and safety of first-line CC-486 plus CHOP in patients with Peripheral T-cell Lymphoma (PTCL) who have received no prior systemic therapy.

Key Inclusion / Exclusion Criteria:

   • Women and men age 18 and older with histologically confirmed diagnosis of Peripheral T-cell Lymphoma 
   • No prior systemic therapy for lymphoma 
   • Detailed eligibility reviewed when you contact the study team

This research study is for pregnant women who have either Crohn’s disease or ulcerative colitis.

Key Inclusion / Exclusion Criteria:
  • Pregnant women with Crohn's disease or ulcerative colitis
  • Age 18 to 50

This clinical trial is a Phase 1 study evaluating the safety of LAM-003 when administered to men and women with previously treated relapsed or refractory AML. Currently, there is a great unmet need for treating AML that has either not responded to or returned after other treatments.

Key Inclusion / Exclusion Criteria:
  • The study is open to men and women aged 18 years or older with a diagnosis of acute myeloid leukemia (AML). 
  • Subjects’ AML must have been previously treated and has progressed during or relapsed after prior therapy. 
  • Detailed eligibility will be reviewed by the study team. 

This clinical trial is open to men age 18 or older who have metastatic prostate cancer to check safety and tolerability of ZEN003694 in combination with enzalutamide. 

Key Inclusion / Exclusion Criteria:
  • Open to men 18 years or older 
  • With metastatic, castrate resistant, confirmed prostate cancer (surgically castrated or continuous medical castration for ≥ 8 weeks prior to screening). 
  • Detailed eligibility reviewed when you contact the study team 

This clinical trial is for men and women with high-grade gliomas that has recurred for the first time. There is currently a need for more effective treatment methods for this disease. 

Key Inclusion / Exclusion Criteria:
  • Open to men and women above the age of 18 who have been diagnosed with high-grade gliomas 
  • Histologically confirmed diagnosis of IDH-mutant high-grade (III or IV) glioma 
  • First recurrence of glioma 
  • Detailed eligibility will be reviewed when you contact the study team 

This clinical trial is for women with metastatic breast cancer. There is currently a need for more effective treatment methods for this disease. 

Key Inclusion / Exclusion Criteria:
  • Open to women age 18 and older 
  • Diagnosed with metastatic breast cancer 
  • Detailed eligibility will be reviewed when you contact the study team

This is a Phase 1/2 Open-label Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial.

Key Inclusion / Exclusion Criteria:
  • Open to men and women 18 years of age and older currently participating in an Astellas-sponsored ASP2215 trial, receiving ASP2215 and able to enroll in this rollover study without interruption of study drug, or with no more than 2 weeks interruption in study drug.
  • Subject must be deriving benefit from continued treatment as determined by the Investigator. 

Detailed eligibility criteria will be reviewed by the study team.

This clinical trial is for patients with locally advanced or metastatic urothelial cancer.

Key Inclusion / Exclusion Criteria:
  • Adults 18 Years and older 
  • Diagnosis of locally advanced or metastatic urothelial cancer 
  • Eligible for CPI therapy and must be either ineligible for first-line cisplatin-based chemotherapy 
  • Detailed eligibility reviewed when you contact the study team. 

Find a Physician

Surgical Services
Weill Cornell Medicine Surgery

Visit our Surgery YouTube channel to view our video library.